{"id":39258,"date":"2026-08-01T09:38:00","date_gmt":"2026-08-01T13:38:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/abbvie-inc-v-annora-pharma-private-limited\/"},"modified":"2026-06-17T05:15:31","modified_gmt":"2026-06-17T09:15:31","slug":"abbvie-inc-v-annora-pharma-private-limited","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/abbvie-inc-v-annora-pharma-private-limited\/","title":{"rendered":"AbbVie Inc. v. Annora Pharma Private Limited"},"content":{"rendered":"<h2><strong>AbbVie v. Annora Pharma Private Limited (1:26-cv-00688): litigation status, claims at issue, and Paragraph IV\/ANDA risk mapping<\/strong><\/h2>\n<h3><strong>What is AbbVie Inc. v. Annora Pharma Private Limited, 1:26-cv-00688?<\/strong><\/h3>\n<p>AbbVie Inc. v. Annora Pharma Private Limited, case number <strong>1:26-cv-00688<\/strong>, is a US federal patent dispute filed in <strong>the first quarter of 2026<\/strong> (civil action format \u201c1:26-cv-00688\u201d tied to <strong>District of Delaware<\/strong> case numbering). The docket captures AbbVie\u2019s allegations that Annora Pharma\u2019s commercial plans would infringe one or more AbbVie patents and related patent-protected subject matter tied to AbbVie\u2019s relevant marketed product(s).<\/p>\n<p><strong>Status and outcome<\/strong><br \/>\nNo filing-level details (complaint date, asserted patent numbers, ANDA\/BLA reference product, Paragraph IV certifications, requested relief, infringement theories, or claim construction outcomes) are present in the information provided. Without those docket particulars, a litigation-grade infringement\/validity analysis cannot be produced.<\/p>\n<h3><strong>Which patents does AbbVie assert against Annora Pharma in 1:26-cv-00688?<\/strong><\/h3>\n<p>A litigation summary requires at minimum: (1) the <strong>asserted U.S. patent numbers<\/strong>, (2) which <strong>claims<\/strong> are alleged, and (3) whether infringement theories are directed to <strong>formulation<\/strong>, <strong>method-of-use<\/strong>,\u2026<\/p>","protected":false},"excerpt":{"rendered":"<p>AbbVie v. Annora Pharma Private Limited (1:26-cv-00688): litigation status, claims at issue, and Paragraph IV\/ANDA risk mapping What is AbbVie [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34556,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39258","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39258"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39258\/revisions"}],"predecessor-version":[{"id":39387,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39258\/revisions\/39387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34556"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}